Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Obinutuzumab Regimen Slows CLL Compared With Rituximab

December 9th 2013

Patients with chronic lymphocytic leukemia and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab instead of rituximab.

Engineered T-Cells Achieve Dramatic Results in Resistant CLL

December 8th 2013

Treatment with engineered donor T cells led to substantial tumor regression in patients with posttransplant relapsed B-cell malignancies, results of a small clinical study showed.

Dr. Goede on Obinutuzumab Versus Rituximab in CLL

December 8th 2013

Valentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.

Dr. Brown on Idelalisib Plus Rituximab in CLL

December 8th 2013

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia.

Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL

December 8th 2013

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approves Frontline Obinutuzumab for CLL

November 1st 2013

The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.

Novel B-Cell Receptor Signaling Inhibitors Show Promise

October 23rd 2013

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.

Positive Idelalisib Data Ends Late-Stage CLL Trial

October 10th 2013

A phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab has been stopped early following a positive interim analysis.

Dr. Woyach on the Role of BTK in CLL

September 20th 2013

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's tyrosine kinase (BTK) in chronic lymphocytic leukemia (CLL).

Ofatumumab Receives Breakthrough Therapy Designation for Earlier Use in CLL

September 16th 2013

The monoclonal antibody ofatumumab has received Breakthrough Therapy designation from the FDA that could allow for earlier use in patients with chronic lymphocytic leukemia.

GA101 Shows Gains in Pivotal CLL Trial

July 26th 2013

Obinutuzumab (GA101), a novel antibody that targets CD20, demonstrated a dramatic advantage in response rates when added to chlorambucil compared with the chemotherapy agent alone in elderly patients with chronic lymphocytic leukemia.

Phase II Data Continue to Back Use of Ibrutinib in CLL

June 19th 2013

Ibrutinib was well tolerated and highly effective in eradicating tumor cells in both treatment-naÃ¯ve and relapsed/refractory patients with chronic lymphocytic leukemia in an ongoing phase II study.

Dr. Goede on the Results from the Phase III CLL11 Trial

June 19th 2013

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukemia

May 15th 2013

The novel selective PI3K-delta inhibitor idelalisib produced rapid and prolonged tumor shrinkage in patients with relapsed or refractory chronic lymphocytic leukemia who received the drug as a monotherapy.

Dr. Jennifer Brown Discusses Rituximab and Ibrutinib in CLL

May 9th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the use of rituximab and ibrutinib in chronic lymphocytic leukemia.

Dr. Jennifer Brown on Ibrutinib and Idelalisib for CLL

April 17th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, and other agents.

Ibrutinib Receives Additional Breakthrough Designation for CLL

April 8th 2013

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Seeking a Standard in the Treatment of Elderly Patients With CLL

March 28th 2013

While there is no standard treatment for most patients with chronic lymphocytic leukemia who are age 65 years and older, several regimens are being tested in clinical trials.

BCR Inhibitors Show Promise in Treating Chronic Lymphocytic Leukemia

March 25th 2013

Two novel, oral drugs that target the B-Cell receptor signal transduction pathway could significantly change the way chronic lymphocytic leukemia is treated.

Dr. Jennifer Brown on Gauging Response in CLL

February 20th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses gauging response in chronic lymphocytic leukemia.